Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1594 of 5804
-
Could a lower steroid dose plus exercise help boys with duchenne?
Disease control CompletedThe study team will determine the potential of low dose twice weekly prednisone and whether exercise training can synergize to delay disease progression and improve muscle strength/physical function in boys with Duchenne muscular dystrophy (DMD). Current standard of care (daily p…
Phase: PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New study tests ocrelizumab in minority MS patients
Disease control CompletedOpen-label, prospective, single-arm, multi-center study to assess disease activity and biomarker of neuronal damage in minority patients (self-identified Black or African American (AA) and Hispanic/Latino (HA) patients with relapsing multiple sclerosis (RMS) receiving treatment w…
Phase: PHASE4 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Stomach cancer drug combo trial halted midway
Disease control TerminatedA Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Phase: PHASE2 • Sponsor: Leap Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New MRI method could replace scalpel for diagnosing head artery disease
Diagnosis Recruiting nowThe research study is being conducted to determine the utility of magnetic resonance imaging (MRI) in identifying inflammation of arteries supplying blood to the head, brain, and eyes. The target population includes patient with suspected giant cell arteritis (GCA; temporal arter…
Sponsor: University of Pennsylvania • Aim: Diagnosis
Last updated Jun 26, 2026 19:14 UTC
-
New drug BMS-986278 tested in 403 lung fibrosis patients
Disease control CompletedThe purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of BMS-986278 in these participants.
Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New ACL surgery combo aims to cut Re-Tear rate in young athletes
Disease control OngoingAnterior cruciate ligament (ACL) rupture is one of the most common musculoskeletal injuries in young individuals, particularly those that are active in sports. Up to 30% of individuals under the age of 20 years suffer a re-injury to the reconstructed ACL. Revision ACLR has been a…
Phase: NA • Sponsor: University of Pittsburgh • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could fewer radiation sessions after surgery improve quality of life for head and neck cancer patients?
Disease control OngoingThere is a strong radiobiological and economic rationale for hypofractionated radiation therapy in head and neck cancer. Phase 1 of the trial aims to assess the acute toxicity and tolerability of hypofractionated radiation therapy in the post-operative setting, and to determine t…
Phase: PHASE1, PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo for kidney cancer shows promise but trial halted early
Disease control TerminatedThis is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of atezolizumab given in combination with cabozantinib versus cabozantinib alone in participants with inoperable, locally advanced, or metastatic renal cell carcinoma (RCC)…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New Nerve-Zapping procedure tested for back pain relief
Symptom relief OngoingThis is an independent prospective, noninterventional, observational post-market data collection of the patient-reported effectiveness, ongoing safety and satisfaction outcomes for patients treated with the Intracept Procedure at a single study site.
Sponsor: University of Utah • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Triple immunotherapy cocktail shows promise in tough cancers
Disease control CompletedThe study will determine Recommended Phase 2 Dose for all study drugs, based on the safety and tolerability of the following combinations: INCAGN02385 + INCAGN02390 and INCAGN02385 + INCAGN02390 + INCMGA00012.
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Experimental drug targets tough blood cancers in first human trial
Disease control CompletedPrimary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and relapsed and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP…
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can vitamin c save burn victims? major trial halted midway
Disease control TerminatedThis study aims to show that giving high dose, intravenous vitamin C in addition to standard care to burned critically ill patients will be associated with less organ dysfunction, improved survival and a quicker rate of recovery. In this study, all patients will receive standard …
Phase: PHASE3 • Sponsor: Clinical Evaluation Research Unit at Kingston General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New weekly shot shows promise for rare bleeding disorder
Disease control CompletedTo select a dose and to make a decision for Phase 3 study
Phase: PHASE2, PHASE3 • Sponsor: Harbour BioMed (Guangzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThe main aim of this study is to check if people with advanced solid tumors have side effects from dazostinag, and to check how much dazostinag they can receive without getting significant side effects from it when given alone and in combination with pembrolizumab. The study will…
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control CompletedThe primary purpose of this study is to define the maximum tolerated dose (MTD) and determine a recommended Phase 2 dose (RP2D) and schedule of orally-administered RP-3500 (camonsertib) alone or in combination with talazoparib, a PARP inhibitor, or Gemcitabine in patients with ad…
Phase: PHASE1, PHASE2 • Sponsor: Repare Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New biosimilar shows promise for treating wet macular degeneration
Disease control CompletedThis is a randomized, double-masked, multicenter study to evaluate the efficacy and safety of FYB203 compared to Eylea® in patients with neovascular age related macular degeneration.
Phase: PHASE3 • Sponsor: Bioeq GmbH • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Better sleep, better stroke recovery? new study tests simple hospital changes
Symptom relief CompletedGiven the critical role of sleep in enhancing neural recovery, motor learning, neuroprotection, and neuroplasticity, interventions to enhance sleep that target sleep could improve recovery and rehabilitation outcomes for stroke patients. In this proposal, a multidisciplinary grou…
Phase: NA • Sponsor: University of Chicago • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Stem cell hope for rare brain disease: 20 patients tracked
Disease control ENROLLING_BY_INVITATIONThe purpose of this study is to measure the effect of Hematopoietic Stem Cell Transplantation (HSCT) on symptoms of CSF1R-related Leukoencephalopathy.
Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug combo targets tough blood cancers
Disease control OngoingThis phase I/II trial studies the side effects and best dose of quizartinib when given with azacitidine and to see how well they work in treating patients with myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasm with FLT3 or CBL mutations. Chemotherapy drugs, …
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental combo targets Hard-to-Treat gut tumors
Disease control OngoingThis phase I trial studies the side effects and best dose of triapine when given together with lutetium Lu 177 dotatate in treating patients with neuroendocrine tumors. Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radioactive…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC